Investor Alert: Argentina Loaded With "White Gold" Opportunity
Experts expect the global lithium market to grow by 500% due to the explosion of electric vehicles and green energy. And one small-cap company just snagged a large lithium deposit in a renowned South American location.
Read about this once-in-a-lifetime opportunity
Saurabh Saha, insider at Centessa Pharmaceuticals
Saurabh Saha Insider Alerts

Get notified the next time Saurabh Saha buys or sells Centessa Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Saurabh Saha Insider Information

Dr. Saurabh Saha, MD, PhD, is Chief Executive Officer and a member of the Board of Directors of Centessa Pharmaceuticals. Most recently, as Senior Vice President of Research & Development at Bristol Myers Squibb Company, Saurabh led translational medicine across all therapeutic areas spanning discovery, early development through late development, and commercialization. In 2019, he led the Research & Development diligence in the acquisition of Celgene by BMS and subsequently managed key aspects of the integration across both organizations. During his tenure, Saurabh laid the foundation for the BMS Research & Development headquarters in Cambridge, Massachusetts, USA serving as site head and establishing a research focus on discovering new cancer treatments for immunotherapy resistance.

Previously, Saurabh was a Venture Partner at Atlas Venture where he held leadership positions with several portfolio biotech companies, including Chief Medical Officer of Synlogic, and Chief Executive Officer of Delinia until its sale to Celgene in early 2017.

In 2008, he established the translational research and development organization at BioMed Valley Discoveries where he served as Chief Scientific Officer and later President and was responsible for leading the development and demonstrating human effectiveness of two first-in-class cancer therapies.

Earlier in his career, Saurabh was a Management Consultant in the pharmaceutical practice at McKinsey & Company and subsequently appointed Director and Head of the New Indications Discovery Unit at Novartis. He is on the editorial boards of several medical journals and is an Associate Member and Global Clinical scholar at Harvard Medical School.

Saurabh holds an MD and PhD in cancer genetics from The Johns Hopkins School of Medicine, where he completed his graduate studies in Bert Vogelstein’s lab. He is an alumnus of Harvard Business School and Oxford University, studying General Management and Biophysics respectively. Saurabh received a BSc in Biochemistry from the California Institute of Technology (Caltech).

How old is Saurabh Saha?

Dr. Saha is currently 44 years old. There are 4 older executives and no younger executives at Centessa Pharmaceuticals. Learn More.

How do I contact Saurabh Saha?

The corporate mailing address for Dr. Saha and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at [email protected]

Has Saurabh Saha been buying or selling shares of Centessa Pharmaceuticals?

During the last ninety days, Saurabh Saha has bought $282,440.00 in shares of Centessa Pharmaceuticals stock. Most recently, on Tuesday, November 16th, Saurabh Saha bought 23,000 shares of Centessa Pharmaceuticals stock. The stock was acquired at an average cost of $12.28 per share, with a total value of $282,440.00.

Who are Centessa Pharmaceuticals' active insiders?

Centessa Pharmaceuticals' insider roster includes Tia Bush (Insider), (Bermuda) Gap (Major Shareholder), Aaron Kantoff (Director), and Saurabh Saha (CEO).

Are insiders buying or selling shares of Centessa Pharmaceuticals?

In the last year, Centessa Pharmaceuticals insiders bought shares 4 times. They purchased a total of 1,538,000 shares worth more than $30,464,540.00. The most recent insider tranaction occured on November, 18th when Director Aaron Kantoff bought 10,000 shares worth more than $119,800.00.

Information on this page was last updated on 11/18/2021.

Saurabh Saha Insider Trading History at Centessa Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2021Buy23,000$12.28$282,440.00View SEC Filing Icon  
See Full Table

Saurabh Saha Buying and Selling Activity at Centessa Pharmaceuticals

This chart shows Saurabh Saha's buying and selling at Centessa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Centessa Pharmaceuticals Company Overview

Centessa Pharmaceuticals logo
Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $11.56
Low: $10.50
High: $12.25

50 Day Range

MA: $15.42
Low: $11.38
High: $22.36

2 Week Range

Now: $11.56
Low: $10.50
High: $26.90

Volume

362,102 shs

Average Volume

222,810 shs

Market Capitalization

$1.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!